RWM
CRL icon

Rialto Wealth Management’s Charles River Laboratories CRL Stock Holding History

Rialto Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.59K Buy
15
+2
+15% +$371 ﹤0.01% 775
2025
Q4 		$2.59K Buy
13
+2
+18% +$363 ﹤0.01% 654
2025
Q3 		$1.72K Hold
11
– – ﹤0.01% 710
2025
Q2 		$1.67K Buy
+11
New +$1.47K ﹤0.01% 662

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rialto Wealth Management's CRL Position: Q1 2026 in Review

Rialto Wealth Management increased its Charles River Laboratories (CRL) stake by 15% in Q1 2026, buying an estimated $371 and bringing the position to 15 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Rialto Wealth Management first reported a position in CRL in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.59K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Rialto Wealth Management held 15 shares of Charles River Laboratories worth $2.59K as of Q1 2026.
  • Rialto Wealth Management bought 2 Charles River Laboratories shares in Q1 2026, an estimated $371.
  • Charles River Laboratories made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #775 holding.
  • Rialto Wealth Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 4 quarters since.
  • Rialto Wealth Management's Charles River Laboratories position peaked at $2.59K in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.